Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921999 · ClinicalTrials.gov registry record
Immune Response to Varicella-Zoster Vaccination and Infection
A clinical trial of Herpes Zoster and Chickenpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT00921999 is a study of Herpes Zoster and Chickenpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 19 participants, below the 2,172-participant average among 16 other Herpes Zoster trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00921999, a study of Herpes Zoster and Chickenpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease. * By drawing and studying blood samples from people who have been infected with the varicella-zoster virus or who are receiving or have received the varicella vaccine, researchers hope to learn more about the immune system s response to the virus. Objectives: \- To determine the immune system s response to the varicella virus, either in its existing form or given as part of a vaccine. Eligibility: * Individuals 18 years of age and older who have had or are receiving the varicella vaccine. * Individuals 5 years of age and older who currently have chickenpox or shingles. Design: * Participants will visit the NIH Clinical Center for an initial physical examination, and will provide blood samples for evaluation. * Researchers will determine the number of samples to be taken and the amount of blood to be drawn as needed based on the participants medical history and exposure to the varicella-zoster virus. Investigators in this study will not be giving subjects either the chickenpox or shingles vaccine. They will only be looking at the response to the vaccine in persons who are receiving or have received the vaccine from their health care provider.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-06-15 |
| Est. Completion | 2015-01-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921999
The ClinicalTrials.gov registry entry for NCT00921999 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,172-participant average among 16 other Herpes Zoster trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 0 interventions.
NCT00921999 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00921999 about?
NCT00921999 is a clinical study titled "Immune Response to Varicella-Zoster Vaccination and Infection". Background: * The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease. * By drawing and studying blood samples from people who have been infected with ...
What is the current status of trial NCT00921999?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2009-06-15. Estimated completion is 2015-01-08.
What conditions does trial NCT00921999 study?
This clinical trial studies the following conditions: Herpes Zoster, Chickenpox.
Who is sponsoring clinical trial NCT00921999?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00921999 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.